Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...

Valeo Financial Advisors LLC decreased its holdings in Sanofi (NASDAQ:SNY – Free Report) by 62.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 </stron ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid <li /> If approved, Dupixent would be the ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

Malonzo THE Philippine Medical Association (PMA) is urging the Philippine government to consider innovative strategies in a ...

With dengue cases surging nationwide, the Philippine Medical Association will urge President Ferdinand "Bongbong" Marcos Jr.

In his first address to staffers at HHS since becoming secretary of the department on Feb. 13, Robert F. Kennedy Jr. Tuesday ...

As global markets navigate through heightened inflation and economic uncertainties, small-cap stocks have been trailing behind their larger counterparts, with the Russell 2000 Index underperforming ...